• Cat-intel
  • MedIntelliX
  • Resources
  • About Us
  • English
    Chinese
    French
    Japanese
    Korean
    German
    Spanish

    Adrenocortical Carcinoma Treatment Market Analysis

    ID: MRFR/Pharma/5105-HCR
    100 Pages
    Rahul Gotadki
    September 2025

    Adrenocortical Carcinoma Treatment Market Research Report Information By Type (Localized Adrenocortical Carcinoma, Metastatic Adrenocortical Carcinoma), Therapy (Radiation Therapy and Others), End-User (Hospitals and Clinics and Others) -Forecast till 2032

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    Adrenocortical Carcinoma Treatment Market Infographic
    $ 4,950.0
    $ 5,950.0
    $ 7,250.0

    Market Analysis

    In-depth Analysis of Adrenocortical Carcinoma Treatment Market Industry Landscape

    Adrenocortical Carcinoma (ACC) Treatment Market is molded by different powerful factors that impact its growth and advancement. This rare and powerful cancer presents a novel arrangement of difficulties, driving a unique scene with regards to research, improvement, and market patterns. ACC is a rare cancer, and its pervasiveness assumes a vital part in market elements. The low occurrence rate makes a specialty market, inciting drug organizations to focus in on specific treatments. This extraordinariness likewise adds to a restricted patient pool, impacting evaluating methodologies and market rivalry. Progressing innovative work endeavors contribute altogether to the elements of the ACC Treatment Market. Novel treatments, designated medications, and immunotherapies are ceaselessly arising, carrying advancement to the market. Clinical preliminaries and cooperative endeavors among the scholarly community and industry players add to the development of treatment choices. ACC treatment envelops a scope of modalities, including surgery, chemotherapy, radiation therapy, and arising immunotherapies. The relative adequacy, security profiles, and patient results related with these modalities add to the market elements. Pushes in customized medication and designated treatments further expand the treatment scene. Market elements are not restricted to laid out markets but rather are additionally impacted by developing markets and globalization patterns. The accessibility of ACC treatments in creating districts, administrative harmonization endeavors, and worldwide organizations add to a more interconnected and dynamic market scene. Expecting the future direction of the ACC Treatment Market includes thinking about continuous exploration, mechanical progressions, and developing patient requirements. Apart from the difficulties, for example, drug advancement costs, market access hindrances, and the requirement for further developed biomarkers present continuous contemplations for partners in this powerful scene.

    Market Summary

    The Global Adrenocortical Carcinoma Treatment Market is projected to grow significantly from 3.82 USD Billion in 2024 to 8.85 USD Billion by 2035.

    Key Market Trends & Highlights

    Global Adrenocortical Carcinoma Treatment Key Trends and Highlights

    • The market is expected to experience a compound annual growth rate (CAGR) of 7.94 percent from 2025 to 2035.
    • By 2035, the market valuation is anticipated to reach 8.85 USD Billion, indicating robust growth potential.
    • In 2024, the market is valued at 3.82 USD Billion, reflecting the current demand for effective treatment options.
    • Growing adoption of advanced treatment modalities due to increasing awareness of adrenocortical carcinoma is a major market driver.

    Market Size & Forecast

    2024 Market Size 3.82 (USD Billion)
    2035 Market Size 8.85 (USD Billion)
    CAGR (2025-2035) 7.94%
    Largest Regional Market Share in 2024 latin_america)

    Major Players

    Arqule, Pfizer Ltd., EnGeneIC Ltd, Exelixis, Inc., Millendo Therapeutics, Inc., Merck & Co., Orphagen Pharmaceuticals, Inc., HRA Pharma, Bristol-Myers Squibb Company, General Electric Company, WG Critical Care, LLC, Mylan N.V., Fresenius Kabi AG, Sinovision Technologies (Beijing) CO., Ltd., Hitachi, Ltd., NeuroLogica Corp., Digirad Corporation

    Market Trends

    The ongoing advancements in therapeutic strategies for adrenocortical carcinoma treatment appear to enhance patient outcomes and may reshape the landscape of oncology care.

    National Cancer Institute

    Adrenocortical Carcinoma Treatment Market Market Drivers

    Market Growth Projections

    Rising Healthcare Expenditure

    The Global Adrenocortical Carcinoma Treatment Market Industry is also benefiting from increasing healthcare expenditure across various regions. Governments and private sectors are investing more in healthcare infrastructure, which facilitates better access to advanced cancer treatments. For instance, countries with robust healthcare systems are allocating significant budgets for oncology, thereby enhancing the availability of cutting-edge therapies for ACC. This trend is expected to drive market growth as more patients gain access to necessary treatments. The anticipated market value of 3.82 USD Billion in 2024 reflects this growing investment in healthcare.

    Emergence of Personalized Medicine

    The emergence of personalized medicine is reshaping the Global Adrenocortical Carcinoma Treatment Market Industry. Tailoring treatment plans based on individual genetic profiles and tumor characteristics allows for more effective and targeted therapies. This approach not only enhances treatment efficacy but also minimizes adverse effects, leading to improved patient satisfaction. As research continues to uncover the genetic underpinnings of ACC, the integration of personalized medicine into treatment protocols is expected to gain momentum. This trend aligns with the overall growth of the market, which is projected to reach 8.85 USD Billion by 2035.

    Advancements in Treatment Modalities

    Innovations in treatment modalities are significantly influencing the Global Adrenocortical Carcinoma Treatment Market Industry. The development of targeted therapies and immunotherapies has shown promise in improving patient outcomes. For instance, the introduction of drugs such as mitotane and novel immunotherapeutic agents has provided new avenues for treatment. These advancements not only enhance survival rates but also reduce the side effects associated with traditional therapies. As these treatment options become more widely available, the market is likely to witness substantial growth, with a projected compound annual growth rate (CAGR) of 7.94% from 2025 to 2035.

    Growing Awareness and Education Initiatives

    Growing awareness and education initiatives regarding adrenocortical carcinoma are playing a crucial role in the Global Adrenocortical Carcinoma Treatment Market Industry. Organizations and healthcare providers are increasingly focusing on educating both the public and healthcare professionals about the signs and symptoms of ACC. This heightened awareness leads to earlier diagnosis and treatment, which is essential for improving patient outcomes. As more individuals become informed about ACC, the demand for effective treatment options is likely to rise, contributing to the market's projected growth trajectory.

    Increasing Incidence of Adrenocortical Carcinoma

    The Global Adrenocortical Carcinoma Treatment Market Industry is experiencing growth due to the rising incidence of adrenocortical carcinoma (ACC). Recent statistics indicate that ACC is a rare but aggressive cancer, with an estimated annual incidence of 0.5 to 2 cases per million people. As awareness increases and diagnostic techniques improve, more cases are being identified, leading to a greater demand for effective treatment options. This trend is expected to contribute to the market's expansion, with projections indicating a market value of 3.82 USD Billion in 2024, potentially reaching 8.85 USD Billion by 2035.

    Market Segment Insights

    Regional Insights

    Key Companies in the Adrenocortical Carcinoma Treatment Market market include

    Industry Developments

    Future Outlook

    Adrenocortical Carcinoma Treatment Market Future Outlook

    The Global Adrenocortical Carcinoma Treatment Market is projected to grow at a 7.94% CAGR from 2024 to 2035, driven by advancements in targeted therapies and increasing awareness.

    New opportunities lie in:

    • Develop personalized treatment plans leveraging genomic profiling.
    • Invest in innovative drug delivery systems to enhance efficacy.
    • Expand clinical trial networks to accelerate drug approvals.

    By 2035, the market is expected to achieve substantial growth, reflecting enhanced treatment options and improved patient outcomes.

    Market Segmentation

    Intended Audience

    • Academic institutes and universities
    • Government research institutes
    • Diagnostic laboratories
    • Research and Development (R&D) companies
    • Oncology research institutes
    • Pharmaceutical companies

    Adrenocortical Carcinoma Treatment Market, by Type

    • Metastatic Adrenocortical Carcinoma
    • Localized Adrenocortical Carcinoma
    • Others
    • Adjuvant Therapy
    • Brachytherapy
    • External beam radiation therapy
    • Radiation Therapy
    • Targeted Therapy
    • Chemotherapy
    • Open surgery
    • Laparoscopic surgery
    • Surgery
    • Cancer Research Institutes
    • Ambulatory Surgical Centers
    • Hospitals and Clinics
    • Americas
    • North America
    • US
    • Canada
    • South America
    • Europe
    • Western Europe
    • Germany
    • France
    • Italy
    • Spain
    • UK
    • Rest of Western Europe
    • Eastern Europe
    • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
    • Middle East & Africa
    • Middle East
    • Africa
    • Academic institutes and universities
    • Government research institutes
    • Diagnostic laboratories
    • Research and Development (R&D) companies
    • Oncology research institutes
    • Pharmaceutical companies

    Adrenocortical Carcinoma Treatment Market, by Region

    • Americas
    • North America
    • US
    • Canada
    • South America
    • Europe
    • Western Europe
    • Germany
    • France
    • Italy
    • Spain
    • UK
    • Rest of Western Europe
    • Eastern Europe
    • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
    • Middle East & Africa
    • Middle East
    • Africa
    • Academic institutes and universities
    • Government research institutes
    • Diagnostic laboratories
    • Research and Development (R&D) companies
    • Oncology research institutes
    • Pharmaceutical companies

    Adrenocortical Carcinoma Treatment Market Key Players

    • and Digirad Corporation 
    • NeuroLogica Corp.
    • Hitachi, Ltd.
    • Sinovision Technologies (Beijing) CO., Ltd.
    • Fresenius Kabi AG
    • Mylan N.V.
    • WG Critical Care, LLC
    • General Electric Company
    • Bristol-Myers Squibb Company
    • HRA Pharma
    • Orphagen Pharmaceuticals, Inc.
    • Merck & Co.
    • Millendo Therapeutics, Inc.
    • Exelixis, Inc.
    • EnGeneIC Ltd
    • Pfizer Ltd.
    • Arqule

    Adrenocortical Carcinoma Treatment Market, by Therapy

    • Others
    • Adjuvant Therapy
    • Brachytherapy
    • External beam radiation therapy
    • Radiation Therapy
    • Targeted Therapy
    • Chemotherapy
    • Open surgery
    • Laparoscopic surgery
    • Surgery
    • Cancer Research Institutes
    • Ambulatory Surgical Centers
    • Hospitals and Clinics
    • Americas
    • North America
    • US
    • Canada
    • South America
    • Europe
    • Western Europe
    • Germany
    • France
    • Italy
    • Spain
    • UK
    • Rest of Western Europe
    • Eastern Europe
    • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
    • Middle East & Africa
    • Middle East
    • Africa
    • Academic institutes and universities
    • Government research institutes
    • Diagnostic laboratories
    • Research and Development (R&D) companies
    • Oncology research institutes
    • Pharmaceutical companies

    Adrenocortical Carcinoma Treatment Market, by End-User

    • Cancer Research Institutes
    • Ambulatory Surgical Centers
    • Hospitals and Clinics
    • Americas
    • North America
    • US
    • Canada
    • South America
    • Europe
    • Western Europe
    • Germany
    • France
    • Italy
    • Spain
    • UK
    • Rest of Western Europe
    • Eastern Europe
    • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
    • Middle East & Africa
    • Middle East
    • Africa
    • Academic institutes and universities
    • Government research institutes
    • Diagnostic laboratories
    • Research and Development (R&D) companies
    • Oncology research institutes
    • Pharmaceutical companies

    Adrenocortical Carcinoma Treatment Market Regional Analysis

    • Metastatic Adrenocortical Carcinoma
    • Localized Adrenocortical Carcinoma
    • Others
    • Adjuvant Therapy
    • Brachytherapy
    • External beam radiation therapy
    • Radiation Therapy
    • Targeted Therapy
    • Chemotherapy
    • Open surgery
    • Laparoscopic surgery
    • Surgery
    • Cancer Research Institutes
    • Ambulatory Surgical Centers
    • Hospitals and Clinics
    • Americas
    • North America
    • US
    • Canada
    • South America
    • Europe
    • Western Europe
    • Germany
    • France
    • Italy
    • Spain
    • UK
    • Rest of Western Europe
    • Eastern Europe
    • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
    • Middle East & Africa
    • Middle East
    • Africa
    • Academic institutes and universities
    • Government research institutes
    • Diagnostic laboratories
    • Research and Development (R&D) companies
    • Oncology research institutes
    • Pharmaceutical companies

    Report Scope

    Report Attribute/Metric Details
    Market Size 2023 3.65 (USD Billion)
    Market Size 2024 3.82 (USD Billion)
    Market Size 2032 8.17 (USD Billion)
    Compound Annual Growth Rate (CAGR) 2.72 % (2024 - 2032)
    Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
    Base Year 2023
    Market Forecast Period 2024 - 2032
    Historical Data 2019 - 2023
      Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
      Key Vendors  Arqule, Pfizer Ltd., EnGeneIC Ltd, Exelixis, Inc., Millendo Therapeutics, Inc., Merck & Co., Orphagen Pharmaceuticals, Inc., HRA Pharma, Bristol-Myers Squibb Company, General Electric Company, WG Critical Care, LLC, Mylan N.V., Fresenius Kabi AG, Sinovision Technologies (Beijing) CO. Ltd. Hitachi Ltd. NeuroLogica Corp., and Digirad Corporation
      Key Market Opportunities   New product launches and R&D Amongst major key Players
      Key Market Drivers Increase in prevalence rates of rare cancers Increased focus of companies on the treatment of adrenocortical carcinomas

    Market Highlights

    Author

    Rahul Gotadki
    Assistant Manager

    She holds an experience of about 6+ years in market research and business consulting, working under the spectrum of information communication technology, telecommunications and semiconductor domains. aarti conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. her expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc.

    Leave a Comment

    Latest Comments

    John Doe

    This is a great article! Really helped me understand the topic better.

    Posted on July 23, 2025, 10:15 AM
    Jane Smith

    Thanks for sharing this. I’ve bookmarked it for later reference.

    Posted on July 22, 2025, 7:45 PM

    FAQs

    What would be the CAGR for Adrenocortical Carcinoma Treatment market during the forecast period of 2024-2032?

    The CAGR for Adrenocortical Carcinoma Treatment market would be 2.72% during the forecast period.

    What could prevent Adrenocortical Carcinoma Treatment market growth?

    Lack of oncology experts and high risk of local occurrence and different metastatic progress can deter Adrenocortical Carcinoma Treatment market growth.

    What are types discussed in the Adrenocortical Carcinoma Treatment market report?

    The types included in Adrenocortical Carcinoma Treatment market report are localized adrenocortical carcinoma and metastatic adrenocortical carcinoma.

    Which region would dominate the Adrenocortical Carcinoma Treatment market?

    The Americas would dominate the Adrenocortical Carcinoma Treatment market.

    Which region would be the fastest-growing in the Adrenocortical Carcinoma Treatment market?

    The APAC region would dominate Adrenocortical Carcinoma Treatment market in terms of growth rate.

    1. 'Table of Contents:     Chapter
    2. Chapter 2.    Market Introduction    
      1.     Definition    
      2.     Scope of the Study    
        1.     Research Objective    
        2.     Assumptions    
        3.     Limitations     Chapter
      3.     Introduction
      4.     Primary Research    
      5.     Secondary Research    
      6.     Market Size Estimation Chapter
      7.     Drivers    
      8.     Restraints
      9.     Opportunities    
      10.     Challenges
      11.     Macroeconomic Indicators
      12.     Technology Trends & Assessment Chapter 5.    Market Factor Analysis
      13.     Porter’s Five Forces Analysis
        1.     Bargaining
    3. Power of Suppliers    
      1.     Bargaining Power of Buyers
        1.     Threat
    4. of New Entrants    
      1.     Threat of Substitutes    
        1.   
    5.  Intensity of Rivalry    
      1.     Value Chain Analysis
      2.     Investment Feasibility Analysis    
      3.     Pricing Analysis Chapter 6.    Global
    6. Adrenocortical Carcinoma Treatment Market, by Type 
      1.     Introduction
      2.        Localized Adrenocortical Carcinoma
    7. Market Estimates & Forecast, by Region, 2020–2027     Market
    8. Estimates & Forecast, by Country, 2020–2027
      1.      Metastatic Adrenocortical Carcinoma Market
    9. Estimates & Forecast, by Region, 2020–2027
    10.     Market Estimates & Forecast, by Country, 2020–2027
    11. Chapter 7.    Global Adrenocortical Carcinoma Treatment Market, by Therapy
      1.     Introduction
      2.     Surgery     7.2.1 Laparoscopic surgery
    12. Market Estimates & Forecast, by Region, 2020–2027     Market
    13. Estimates & Forecast, by Country, 2020–2027
    14.     7.2.2 Open surgery
    15. Market Estimates & Forecast, by Region, 2020–2027
    16.     Market Estimates & Forecast, by Country, 2020–2027
      1.     Chemotherapy Market Estimates
    17. Forecast, by Region, 2020–2027
    18.     Market Estimates & Forecast, by Country, 2020–2027
      1.     Targeted Therapy Market
    19. Estimates & Forecast, by Region, 2020–2027
    20.     Market Estimates & Forecast, by Country, 2020–2027
      1.     Radiation Therapy
        1. External beam radiation therapy
    21. Market Estimates & Forecast, by Region, 2020–2027
    22.     Market Estimates & Forecast, by Country, 2020–2027     7.5.2 Brachytherapy Market
    23. Estimates & Forecast, by Region, 2020–2027
    24.     Market Estimates & Forecast, by Country, 2020–2027
      1.     Adjuvant Therapy
    25. Market Estimates & Forecast, by Region, 2020–2027     Market
    26. Estimates & Forecast, by Country, 2020–2027
      1.     Others
    27. Market Estimates & Forecast, by Region, 2020–2027     Market
    28. Estimates & Forecast, by Country, 2020–2027 Chapter 8.    Global
    29. Adrenocortical Carcinoma Treatment Market, by End-User
      1.     Introduction
      2.     Hospitals and Clinics Market
    30. Estimates & Forecast, by Region, 2020–2027
    31. Market Estimates & Forecast, by Country, 2020–2027
      1.     Ambulatory Surgical Centers Market
    32. Estimates & Forecast, by Region, 2020–2027
    33. Market Estimates & Forecast, by Country, 2020–2027
      1.     Cancer Research Institutes Market
    34. Estimates & Forecast, by Region, 2020–2027
    35. Market Estimates & Forecast, by Country, 2020–2027 Chapter 9.  
    36.  Global Adrenocortical Carcinoma Treatment, by Region
      1.     Introduction
      2.     Americas
        1.     North America
        2.     South America
      3.     Europe
        1.     Western Europe
    37.  Rest of Western Europe
      1.     Eastern Europe
      2.     Asia-Pacific
        1.     Japan
        2.     China
        3.     India
        4.     Australia
        5.     South Korea
        6.     Rest of Asia-Pacific
      3.     Middle East & Africa
        1.     Middle East
        2.      Africa Chapter 10.    Company Landscape    
      4.     Introduction    
      5.     Market Share Analysis    
      6.     Key Development & Strategies     Chapter
      7.     Arqule
        1.     Company Overview    
        2.     Product Overview    
        3.     Financials Overview
        4.     Key Developments    
        5.     SWOT Analysis    
      8.     Pfizer Ltd.
        1.     Company Overview    
        2.     Product Overview    
        3.     Financial Overview    
        4.     Key Developments    
        5.     SWOT Analysis    
      9.     EnGeneIC Ltd
        1.     Company Overview    
        2.     Product Overview    
        3.     Financial Overview
        4.     Key Development    
        5.     SWOT Analysis    
      10.      Exelixis, Inc.
        1.     Company Overview    
        2.     Product Overview    
        3.     Financial Overview    
        4.     Key Development    
        5.     SWOT Analysis    
      11.     Millendo Therapeutics, Inc.
        1.     Company Overview    
        2.     Product Overview    
        3.     Financial overview    
        4.     Key Developments
        5.     SWOT Analysis        
      12.     Merck & Co.
        1.     Company Overview    
        2.     Product Overview    
        3.     Financial Overview    
        4.     Key Developments
        5.   
    38.  SWOT Analysis        
      1.     Orphagen Pharmaceuticals, Inc.
        1.     Overview    
        2.     Product Overview    
        3.     Financial Overview    
        4.     Key Developments    
        5.     SWOT Analysis    
      2.     HRA Pharma
        1.     Overview    
        2.     Product Overview
        3.     Financials    
        4.     Key Developments    
        5.     SWOT Analysis
      3.     Bristol-Myers Squibb Company
        1.     Overview    
        2.     Product Overview    
        3.     Financials    
        4.     Key Developments    
        5.     SWOT Analysis
      4.   General Electric Company
        1.     Overview    
        2.     Product Overview    
        3.     Financials    
        4.     Key Developments    
        5.     SWOT Analysis
      5.     WG Critical Care, LLC
        1.     Overview    
        2.     Product Overview    
        3.     Financials    
        4.     Key Developments    
        5.     SWOT Analysis
      6.     Mylan N.V.
        1.     Overview    
        2.     Product Overview    
        3.     Financials    
        4.     Key Developments    
        5.     SWOT Analysis
      7.     Fresenius Kabi AG
        1.     Overview    
        2.     Product Overview    
        3.     Financials    
        4.     Key Developments    
        5.     SWOT Analysis
      8.     SINOVISION Technologies (Beijing)CO., Ltd.
        1.     Overview    
        2.     Product Overview    
        3.     Financials    
        4.     Key Developments    
        5.     SWOT Analysis
      9.     Hitachi, Ltd. 
        1.     Overview    
        2.     Product Overview    
        3.     Financials    
        4.     Key Developments    
        5.     SWOT Analysis
      10.     NeuroLogica Corp.
        1.     Overview    
        2.     Product Overview    
        3.     Financials    
        4.     Key Developments    
        5.     SWOT Analysis
      11.     Digirad Corporation
        1.     Overview    
        2.     Product Overview    
        3.     Financials    
        4.     Key Developments    
        5.     SWOT Analysis Chapter 12    MRFR Conclusion    
      12.     Key Findings    
        1.     From CEO’s Viewpoint    
        2.     Unmet Needs of the Market    
      13.   
    39.  Key Companies to Watch    
      1.     Predictions for the Adrenocortical Carcinoma Treatment Industry Chapter 13.    Appendix  
    40. Carcinoma Treatment Market Synopsis, 2020–2027
    41. Treatment Market Estimates and Forecast, 2020–2027 (USD Million)
    42.  Global Adrenocortical Carcinoma Treatment Market, by Type, 2020–2027 (USD Million)
    43. 4    Global Adrenocortical Carcinoma Treatment Market, by Therapy, 2020–2027 (USD Million)
    44. Market, by End-User, 2020–2027 (USD Million)
    45. Adrenocortical Carcinoma Treatment Market, by Region, 2020–2027(USD Million)
    46. America: Adrenocortical Carcinoma Treatment Market, by Type, 2020–2027 (USD
    47. Million)                    
    48. America: Adrenocortical Carcinoma Treatment Market, by Therapy, 2020–2027 (USD Million)
    49. 9    North America: Adrenocortical Carcinoma Treatment Market, by
    50. End-User, 2020–2027 (USD Million)
    51. Carcinoma Treatment Market, by Region, 2020–2027 (USD Million)
    52. Adrenocortical Carcinoma Treatment Market, by Type, 2020–2027 (USD Million)
    53.  US: Adrenocortical Carcinoma Treatment Market, by Therapy, 2020–2027 (USD Million)
    54. 13    US: Adrenocortical Carcinoma Treatment Market, by End-User, 2020–2027 (USD Million)
    55. by Region, 2020–2027 (USD Million)
    56. Treatment Market, by Type, 2020–2027 (USD Million)
    57. Carcinoma Treatment Market, by Therapy, 2020–2027 (USD Million)
    58.  Canada: Adrenocortical Carcinoma Treatment Market, by End-User, 2020–2027 (USD Million)
    59. 18    Canada: Adrenocortical Carcinoma Treatment Market, by Region, 2020–2027 (USD Million)
    60. Treatment Market, by Type, 2020–2027 (USD Million)
    61. Carcinoma Treatment Market, by Therapy, 2020–2027 (USD Million)
    62.  South America: Adrenocortical Carcinoma Treatment Market, by End-User, 2020–2027 (USD Million)
    63. 22    South America: Adrenocortical Carcinoma Treatment Market, by
    64. Region, 2020–2027 (USD Million)            
    65.           
    66. Treatment Market, by Type, 2020–2027 (USD Million)
    67. Carcinoma Treatment Market, by Therapy, 2020–2027 (USD Million)
    68.  Europe: Adrenocortical Carcinoma Treatment Market, by End-User, 2020–2027 (USD Million)
    69. 26    Europe: Adrenocortical Carcinoma Treatment Market, by Region
    70. 2020–2027 (USD Million)                
    71.        
    72. Treatment Market, by Type, 2020–2027 (USD Million)        
    73.  Western Europe: Adrenocortical Carcinoma Treatment Market, by Therapy, 2020–2027
    74. (USD Million)                     
    75.  Western Europe: Adrenocortical Carcinoma Treatment Market, by End-User, 2020–2027
    76. (USD Million)                          
    77. 30    Western Europe: Adrenocortical Carcinoma Treatment Market
    78. by Region, 2020–2027 (USD Million)            
    79.              
    80. Carcinoma Treatment Market, by Type, 2020–2027 (USD Million)    
    81.        
    82. Treatment Market, by Therapy, 2020–2027 (USD Million)      
    83.        
    84. Treatment Market, by End-User, 2020–2027 (USD Million)      
    85.                    
    86.  Eastern Europe: Adrenocortical Carcinoma Treatment Market, by Region, 2020–2027
    87. (USD Million)                         
    88. 33    Asia-Pacific: Adrenocortical Carcinoma Treatment Market, by
    89. Type, 2020–2027 (USD Million)              
    90.            
    91. Carcinoma Treatment Market, by Therapy, 2020–2027 (USD Million)
    92.  Asia-Pacific: Adrenocortical Carcinoma Treatment Market, by End-User, 2020–2027
    93. (USD Million)                        
    94. 35    Asia-Pacific: Adrenocortical Carcinoma Treatment Market, by
    95. Region, 2020–2027 (USD Million)            
    96.                        
    97.         
    98. Carcinoma Treatment Market, by Type, 2020–2027 (USD Million)      
    99. 37    Middle East & Africa: Adrenocortical Carcinoma Treatment
    100. Market, by Therapy, 2020–2027 (USD Million)          
    101.                        
    102.              
    103. Adrenocortical Carcinoma Treatment Market, by End-User, 2020–2027 (USD Million)
    104.                         
    105.  Middle East & Africa: Adrenocortical Carcinoma Treatment Market, by Region, 2020–2027 (USD Million)
    106.                           LIST OF FIGURES 1    Research Process Carcinoma Treatment Market
    107. Adrenocortical Carcinoma Treatment Market
    108. Carcinoma Treatment Market Share, by Type, 2020 (%)
    109. Carcinoma Treatment Market Share, by Therapy, 2020 (%)
    110. Carcinoma Treatment Market Share, by End-User, 2020 (%)
    111. Carcinoma Treatment Market Share, by Region, 2020 (%)
    112. Carcinoma Treatment Market Share, by Country, 2020 (%)
    113. Carcinoma Treatment Market Share, by Country, 2020 (%)
    114. Carcinoma Treatment Market Share, by Country, 2020 (%)
    115. Adrenocortical Carcinoma Treatment Market Share, by Country, 2020 (%)
    116.  Global Adrenocortical Carcinoma Treatment Market: Company Share Analysis
    117. 2020 (%)
    118. 13    Arqule: Key Financials
    119.       Arqule: Geographical Revenue
    120.  Pfizer Ltd.: Segmental Revenue
    121.  EnGeneIC Ltd: Key Financials
    122.  EnGeneIC Ltd: Geographical Revenue
    123.  Exelixis, Inc.: Segmental Revenue Revenue
    124. 25    Millendo Therapeutics, Inc.: Key Financials
    125. Therapeutics, Inc.: Segmental Revenue Geographical Revenue
    126. 28    Merck & Co.: Key Financials Revenue
    127.  Orphagen Pharmaceuticals, Inc.: Key Financials Inc.: Segmental Revenue Revenue
    128. 34    HRA Pharma: Key Financials Revenue
    129. 36    HRA Pharma: Geographical Revenue Company: Key Financials Segmental Revenue
    130. 39    Bristol-Myers Squibb Company: Geographical Revenue 
    131.  General Electric Company: Key Financials Segmental Revenue
    132. 42    General Electric Company: Geographical Revenue
    133. Critical Care, LLC: Key Financials Revenue
    134. 45    WG Critical Care, LLC: Geographical Revenue 
    135.  Mylan N.V.: Key Financials
    136.  Mylan N.V.: Geographical Revenue  Financials
    137. 50    Fresenius Kabi AG: Segmental Revenue Revenue 
    138. 52    SINOVISION Technologies (Beijing)CO.,Ltd.: Key Financials
    139.  SINOVISION Technologies (Beijing)CO.,Ltd.: Segmental Revenue
    140. Technologies (Beijing)CO.,Ltd.: Geographical Revenue 
    141.  Hitachi, Ltd.: Segmental Revenue Revenue
    142. 58    NeuroLogica Corp.: Key Financials Revenue
    143. 60    NeuroLogica Corp.: Geographical Revenue Key Financials
    144. 62    Digirad Corporation: Segmental Revenue Geographical Revenue'

    Adrenocortical Carcinoma Treatment Market Segmentation

    Market Segmentation Overview

    • Detailed segmentation data will be available in the full report
    • Comprehensive analysis by multiple parameters
    • Regional and country-level breakdowns
    • Market size forecasts by segment
    Infographic

    Free Sample Request

    Kindly complete the form below to receive a free sample of this Report

    Get Free Sample

    Customer Strories

    “I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

    Victoria Milne

    Founder
    Case Study
    Chemicals and Materials